CSAM News
DEA Hosts Public Listening Sessions on Telemedicine Regulations on September 12-13, 2023
WASHINGTON – The Drug Enforcement Administration will host public listening sessions to receive comments from healthcare practitioners, experts, advocates, patients, and other members of the public to inform DEA’s regulations on prescribing controlled substances via telemedicine. The listening sessions will be held in person and livestreamed with remote participation available.
WHAT: Public Listening Sessions on Telemedicine Regulations
WHO: Open to the public
WHEN: September 12-13, 2023
WHERE: DEA Headquarters, 700 Army Navy Drive, Arlington, Va. 22202
FOR MEMBERS OF THE PUBLIC: Beginning on August 7, members of the public wishing to attend in person (space permitting) must register HERE by August 21, 2023 at 11:59 p.m. DEA is accepting requests to make limited oral presentations during the public meeting. Persons wishing to give an oral presentation – in person or virtually – time permitting, must indicate the desire to present when requesting to register. Presentations will be limited to 10 minutes.
U.S. House Vote Tomorrow (May 25): Oppose Harsh Drug Penalties
FROM THE DRUG POLICY ALLIANCE:
The U.S. House will vote on the HALT Fentanyl Act tomorrow. This misguided bill would ramp up harsh mandatory minimum sentences for fentanyl analogues. And it would permanently make all fentanyl-related substances Schedule I without first testing them for benefits or harm.
Criminalization has failed to keep us safer. Instead, it’s actually fueling the tragic overdose crisis. Increasing penalties will only make things worse.
Saving lives requires a health approach, not more punishment. This bill is a step in the wrong direction. Help us to oppose it: tell your Representative to vote against the HALT Fentanyl Act right now.
We expect this vote to be close so it’s vital for constituents like you to also make…
Nominations Open for the 2023 Vernelle Fox & Community Service Awards!
CSAM is now accepting nomination submissions for the Vernelle Fox & Community Service Awards!
Honoring an Inquiring Mind, Courage, and Enthusiasm
- Inquiring Mind – Contributions to the understanding of the field
- Courage – Resolution and tenacity
- Enthusiasm – Energy for the positive
CSAM recognizes physicians who have made noteworthy and lasting contributions in line with the mission of the Society: contributions which improve the quality of health care services, increase communication and education among providers of care and add to the research on which the understanding of the field is based and on which the health care services are built.
This award will be presented to the selected candidate during the CSAM 2023 Addiction Medicine Review Course and Board Exam Preparation Track.
If you have someone in mind you feel is worthy of the Vernelle Fox Award, please CLICK HERE to submit a nomination on their behalf.
Please submit your nomination by June 15, 2023!
Recognizing non-physicians who make outstanding contributions to the community
The Community Service award recognizes a non-physician who made outstanding contributions to the community. This CSAM award is presented based on merit and since 1985, it has been awarded to a wide variety of legislators, activists, community leaders, etc., all with one thing in common: they have improved the lives of those suffering from the disease of addiction, and by doing so have contributed a valuable service to the community.
This award will be presented to the selected candidate during the CSAM 2023 Addiction Medicine Review Course and Board Exam Preparation Track.
If you have someone in mind you feel is worthy of the Community Service Award, please CLICK HERE to submit a nomination on their behalf.
Please submit your nomination by June 15, 2023!
CSAM Spring 2023 Newsletter
CSAM News: The Voice for Treatment | Spring 2023
Included in this issue: Letter from the CSAM President, Karen Miotto, Message from the CSAM Conference Committee Chair, MERF Update, How I Ended Up in Addiction Medicine by CSAM President Elect Sharone Abramowitz MD FASAM, CSAM Government Affairs Committee Update, Case Discussions are Back! by CSAM Secretary Dana Harris MD, CSAM Interview with CA Bridge Program Co-Founder Andrew Herring with Ingeborg Schafhalter MD, ABPM Practice Pathway Sunsetting by Chwen-Yuen Angie Chen MD FACP FASAM, PRESS RELEASE: Victory for Public Health: U.S. Supreme Court Refuses to Hear Tobacco Industry’s Challenge to Los Angeles County Law Ending Flavored Tobacco Sales, Tobacco Cessation in Substance Use Treatment: Research & Policy Efforts to Reduce Tobacco-Related Health Inequality by Chwen-Yuen Angie Chen MD FACP FASAM, and A 50 Year CSAM Celebration!
Read the Newsletter Here!
Governor Newsom Releases Master Plan for Tackling the Fentanyl and Opioid Crisis
Governor Newsom has invested over $1 billion to tackle the crisis
Through CalRx, California will seek to manufacture its own Naloxone
Master Plan provides comprehensive approach to save more lives
SAN DIEGO COUNTY – Today, following a visit to the San Ysidro Port of Entry, Governor Gavin Newsom released his administration’s Master Plan for Tackling the Fentanyl and Opioid Crisis. Recognizing the opioid and fentanyl crisis as a multifaceted public health and public safety issue, Governor Newsom’s Master Plan provides a comprehensive approach to save lives. The Master Plan builds on the Governor’s $1 billion investment to tackle this crisis — including an expansion of California National Guard-supported operations that last year led to a 594% increase in seized fentanyl. The Master Plan outlines aggressive steps to support overdose prevention efforts, hold the opioid pharmaceutical industry accountable, crack down on drug trafficking, and raise awareness about the dangers of opioids, including fentanyl.
WHAT GOVERNOR NEWSOM SAID: “Over 150 people die every day in our nation from overdoses and poisonings related to synthetic opioids like fentanyl. Enough. With this Master Plan, California is doubling down to combat this crisis and save lives. Our comprehensive approach will expand enforcement efforts to crack down on transnational criminal organizations trafficking this poison into our communities — while prioritizing harm reduction strategies to reduce overdoses and compassionately help those struggling with substance use and addiction.”
View the Master Plan
DEA Announces Important Change to Registration Requirement
On December 29, 2022, with the signing of the Consolidated Appropriations Act of 2023 (the Act), Congress eliminated the “DATA-Waiver Program.”
All DEA registrants should be aware of the following:
- A DATA-Waiver registration is no longer required to treat patients with buprenorphine for opioid use disorder.
- Going forward, all prescriptions for buprenorphine only require a standard DEA registration number. The previously used DATA-Waiver registration numbers are no longer…
End of Buprenorphine X-Waiver
After almost twenty years of intense medication specific government regulation buprenorphine is now just like other schedule III medications. The era of limited numbers of treatment slots that started at 30 patients per provider who had completed 8 hours of specific training, requirements to maintain lists of patients who received prescriptions and even in person visits by DEA agents to a large…